<DOC>
	<DOCNO>NCT02049580</DOCNO>
	<brief_summary>Study test feasibility efficacy T-replete Bone Marrow ( BM ) , infused RIC regimen post-transplantation Cyclophosphamide ( Cy ) , patient poor prognosis lymphoma .</brief_summary>
	<brief_title>Reduced Intensity Conditioning ( RIC ) Regimen Post-transplant Cyclophosphamide Haploidentical Bone Marrow Transplantation Patients With Poor Prognosis Lymphomas</brief_title>
	<detailed_description>Allogeneic stem cell transplantation ( ALLO ) treatment choice many hematological disease . However , HLA identical donor ( sibling unrelated ) available 50-60 % patient alternative donor need . Haploidentical donor use many year , mostly extensive T-cell depletion peripheral stem cell , avoid Graft Versus Host Disease ( GVHD ) . Recently , promise data report haploidentical transplantation use T-replete bone marrow ( BM ) high-dose cyclophosphamide ( Cy ) post-transplantation . However , condition regimen contain drug active hemopathies , enhance relapse risk . In study , investigator want test feasibility efficacy T-replete BM , infuse RIC regimen post-transplantation Cy , patient poor prognosis lymphoproliferative disease . The RIC regimen consist modified regimen use different study conduct Italy behalf GITMO .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Signed date IECapproved inform consent Age ≥ 1870 year old . Performance Status Karnofsky ≥ 80 % ( see appendix B ) HLA type perform high resolution ( allele level ) HLAA , HLA B , HLA Cw , HLADRB1 , HLADQB1 locus . A minimum match 5/10 require . An unrelated donor search require patient eligible protocol clinical situation dictate urgent transplant . The donor recipient must identical , determine high resolution typing , least one allele follow genetic locus : HLAA , HLAB , HLACw , HLADRB1 , HLADQB1 . Patients lymphoma ( histology ) relapse high dose chemotherapy partial remission , complete remission stable disease last CT line . 1 . Hodgkin 's lymphoma : Patients refractory least 2 CT line , include tandem autoallo program 2 . Diffuse large B cell lymphoma : Refractory second line salvage chemotherapy ( patient partial remission , stable disease progressive ) . These patient partial remission , complete remission stable disease one CT line . 3 . Peripheral T cell lymphoma : Patients fail achieve complete remission first line CT. 4 . Low grade lymphoma ( follicular non follicular : Patients refractory rituximab containing regimen . Patients relapse least 2 line CT . The duration remission &lt; 1 year . 5 . Chronic lymphatic leukemia : Patients refractory relapse ( response duration &lt; 1 year ) disease RFludarabine CT 6 . Mantle cell lymphoma : Patients relapse refractory first line conventional CT . Absence HLA identical sibling 10/10 unrelated donor Patients adequate physical function measure : Cardiac : Left ventricular ejection fraction rest must ≥ 40 % Hepatic : Bilirubin ≤ 2.5 mg/dL ; ALT , AST , Alkaline Phosphatase ≤ 5 x ULN . Renal : Creatinine clearance GFR ≥ 50 mL/min/1.73 m2 . Pulmonary : FEV1 , FVC , DLCO ≥ 50 % predict ( correct hemoglobin ) ; unable perform pulmonary function test , O2 saturation ≥ 92 % room air . Presence HLAmatched , relate donor ( HLAA , B , DRB1 ) Presence match unrelated donor ( 10/10 ) , available time . Pregnancy breastfeed . Evidence HIV infection know HIV positive serology . Current uncontrolled bacterial , viral fungal infection Evidence progression clinical symptom radiologic finding . Prior allogeneic hematopoietic stem cell transplant . Central Nervous System ( CNS ) lymphoma localization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>lymphoma</keyword>
</DOC>